|
11.12.2024 11:45:00
|
Karolinska Development’s Chairman of the Board resigns at his own request
STOCKHOLM, SWEDEN – December 11, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the company’s Chairman of the Board, Professor Hans Wigzell, has decided to resign from his position. The Board of Directors will immediately initiate a process to appoint a new Chairman.
Hans Wigzell has been an instrumental force in Karolinska Development ever since the company was founded. He has served as Chairman of the Board during several periods, most recently since the 2024 Annual General Meeting.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com
This information is information that Karolinska Development is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-12-11 11:45 CET.
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patient’s lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com.
Attachment
Analysen zu Karolinska Development AB (B)
Mut zum Risiko – BX Morningcall mit Dr. Ralf Seiz & François Bloch
🔔🔔🔔 Im heutigen BX Morningcall Spezial gibt Dr. Ralf Seiz, CEO und Gründer der Finreon AG, spannende Einblicke in innovative Anlagelösungen. Als Spin-off der Universität St. Gallen bietet Finreon Strategien an, die Diversifikation und Risikomanagement vereinen – unter anderem durch die systematische Reduktion von Aktienkonzentrationen und die Nutzung von Volatilitätsprämien.
Zusammen mit dem Investmentstrategen François Bloch und Olivia Hähnel von BX Swiss spricht der promovierte Ökonom auch über die aktuellen wirtschaftlichen Herausforderungen und gibt exklusive Einblicke in seine persönlichen Anlageprojekte.
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Karolinska Development AB (B) | 1.11 | 8.59% |
|
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
US-Inflationsdaten im Blick: US-Börsen schliessen uneinheitlich - Techrekorde -- SMI schliesst im Plus -- DAX beendet Handel fester -- Börsen in Fernost schliessen zurückhaltend - Hang Seng im MinusDie heimische Börse zeigte sich am Mittwoch mit Gewinnen. Der deutsche Leitindex präsentierte sich letztendlich ebenso höher. Die US-Börsen zeigten sich uneinheitlich. Die asiatischen Aktienmärkte tendierten unterdessen zur Wochenmitte uneinheitlich.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |